The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Open accessAbstract
Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific killer-cell-engager antibody formats directed against tumor cells and stimulating anti-tumor T cell immunity has proved challenging, mostly due to toxicity problems. We report here the generation of trifunctional natural killer (NK) cell engagers (NKCEs), targeting two activating receptors, NKp46 and CD16, on NK cells and a tumor antigen on cancer cells. Trifunctional NKCEs were more potent in vitro than clinical therapeutic antibodies targeting the same tumor antigen. They had similar in vivo pharmacokinetics to full IgG antibodies and no off-target effects and efficiently controlled tumor growth in mouse models of solid and invasive tumors. Trifunctional NKCEs thus constitute a new generation of molecules for fighting cancer. VIDEO ABSTRACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Scaling and assessment of data quality
Evans, P. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905036693 · Cited by 4,374
Molecular replacement with MOLREP
Vagin, A., & Teplyakov, A. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042589 · Cited by 3,604
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Innate Lymphoid Cells: 10 Years On
Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,124
Self-citationCartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Self-citationRecognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells
Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T. I., Bushkin, Y., Davis, D. M., Strominger, J. L., Yewdell, J. W., & Porgador, A. (2001) · Nature · doi:10.1038/35059110 · Cited by 990
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS
Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M. C., & Moretta, L. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.619 · Cited by 875
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Self-citationDifferential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Refinement of severely incomplete structures with maximum likelihood in BUSTER–TNT
Blanc, E., Roversi, P., Vonrhein, C., Flensburg, C., Lea, S. M., & Bricogne, G. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904016427 · Cited by 717
Mamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Self-citationActivation, coactivation, and costimulation of resting human natural killer cells
Bryceson, Y. T., March, M. E., Ljunggren, H., & Long, E. O. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00457.x · Cited by 650
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.953 · Cited by 579
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 576
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D., & Tabi, Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7249 · Cited by 574
p46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell Activation
Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C., Moretta, L., & Moretta, A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1129 · Cited by 554
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4179 · Cited by 512
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46
Walzer, T., Bléry, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S. H., Jaeger, S., André, P., Gauthier, L., Daniel, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609692104 · Cited by 476
Self-citationKlinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
Sivori, S., Pende, D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., & Moretta, A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199905)29:05<1656::aid-immu1656>3.0.co;2-1 · Cited by 422
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Remark, R., Alifano, M., Cremer, I., Lupo, A., Dieu-Nosjean, M.-C., Riquet, M., Crozet, L., Ouakrim, H., Goc, J., Cazes, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3847 · Cited by 375
Self-citationRothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., & Plymate, S. R. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422206 · Cited by 330
TGF- downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients
Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop009 · Cited by 322
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Dennler, P., Chiotellis, A., Fischer, E., Brégeon, D., Belmant, C., Gauthier, L., Lhospice, F., Romagne, F., & Schibli, R. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400574z · Cited by 292
Self-citationBryceson, Y. T., Ljunggren, H.-G., & Long, E. O. (2009) · Blood · doi:10.1182/blood-2009-01-201632 · Cited by 286
Surface NK receptors and their ligands on tumor cells
Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M. C., & Moretta, A. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.002 · Cited by 283
Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
Sun, L. L., Ellerman, D., Mathieu, M., Hristopoulos, M., Chen, X., Li, Y., Yan, X., Clark, R., Reyes, A., Stefanich, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4802 · Cited by 275
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
Moore, P. A., Zhang, W., Rainey, G. J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M. C., Aggarwal, S., Yang, Y., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306449 · Cited by 260
Targeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
Self-citationCARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0297 · Cited by 228
Glasner, A., Levi, A., Enk, J., Isaacson, B., Viukov, S., Orlanski, S., Scope, A., Neuman, T., Enk, C. D., Hanna, J. H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.007 · Cited by 222
Kebenko, M., Goebeler, M.-E., Wolf, M., Hasenburg, A., Seggewiss-Bernhardt, R., Ritter, B., Rautenberg, B., Atanackovic, D., Kratzer, A., Rottman, J. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1450710 · Cited by 177
Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1
Glasner, A., Ghadially, H., Gur, C., Stanietsky, N., Tsukerman, P., Enk, J., & Mandelboim, O. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102461 · Cited by 176
Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR1
Halfteck, G. G., Elboim, M., Gur, C., Achdout, H., Ghadially, H., & Mandelboim, O. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801878 · Cited by 162
SLAM family receptors in normal immunity and immune pathologies
Wu, N., & Veillette, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.003 · Cited by 152
Role of natural killer cells in cancer.
Pross, H. F., & Lotzová, E. (1994) · PubMed · Cited by 151
Complement factor P is a ligand for the natural killer cell–activating receptor NKp46
Narni-Mancinelli, É., Gauthier, L., Baratin, M., Guia, S., Fenis, A., Deghmane, A., Rossi, B., Fourquet, P., Escalière, B., Kerdiles, Y. M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aam9628 · Cited by 144
Self-citationEckl, J., Büchner, A., Prinz, P. U., Riesenberg, R., Siegert, S. I., Kammerer, R., Nelson, P. J., & Noeßner, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0806-7 · Cited by 142
Shields, M. A., Dangi-Garimella, S. Y., Krantz, S. B., Bentrem, D. J., & Munshi, H. G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.195628 · Cited by 129
Hoffman, L. M., & Gore, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00063 · Cited by 129
NK Cells and Cancer Immunoediting
Guillerey, C., & Smyth, M. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_446 · Cited by 110
Vallera, D. A., Zhang, B., Gleason, M., Oh, S., Weiner, L. M., Kaufman, D. S., McCullar, V., Miller, J. S., & Verneris, M. R. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1329 · Cited by 105
Oberg, H., Kellner, C., Gonnermann, D., Sebens, S., Bauerschlag, D., Gramatzki, M., Kabelitz, D., Peipp, M., & Wesch, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00814 · Cited by 96
Schmohl, J., Felices, M., Oh, F., Lenvik, A. J., LeBeau, A. M., Panyam, J., Miller, J. S., & Vallera, D. A. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.491 · Cited by 92
Amann, M., Brischwein, K., Lutterbuese, P., Parr, L., Petersen, L., Lorenczewski, G., Krinner, E., Bruckmeier, S., Lippold, S., Kischel, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2182 · Cited by 90
Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 86
Schmohl, J. U., Felices, M., Todhunter, D., Taras, E. P., Miller, J. S., & Vallera, D. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12073 · Cited by 67
Saito, H., Osaki, T., & Ikeguchi, M. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0059-8 · Cited by 65
Ying, T., Chen, W., Gong, R., Feng, Y., & Dimitrov, D. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.368647 · Cited by 64
Activating and inhibitory receptors expressed on innate lymphoid cells
Guia, S., Fenis, A., Vivier, É., & Narni-Mancinelli, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0685-x · Cited by 63
Tumor-derived soluble MICs impair CD3+CD56+ NKT-like cell cytotoxicity in cancer patients
WANG, H., Yang, D., XU, W., Wang, Y., Ruan, Z., Zhao, T., Han, J., & Wu, Y. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.07.001 · Cited by 59
Street, S. E. A., Zerafa, N., Iezzi, M., Westwood, J. A., Stagg, J., Musiani, P., & Smyth, M. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4084 · Cited by 52
Checkpoint inhibition in pediatric hematologic malignancies
Davis, K. L., Agarwal, A. M., & Verma, A. R. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1383542 · Cited by 36
Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade
Mittal, D., Vijayan, D., & Smyth, M. J. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0798 · Cited by 34
Molecular insight into targeting the NK cell immune response to cancer
Rautela, J., Souza-Fonseca-Guimarães, F., Hediyeh-zadeh, S., Delconte, R. B., Davis, M. J., & Huntington, N. D. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12045 · Cited by 32
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy
Koch, J., & Tesar, M. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479981 · Cited by 23
Cited by
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Self-citationNatural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Metadata
- Authors
- Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., Rispaud-Blanc, H., Guillot, F., Cornen, S., Roussel, A., Amigues, B., Habif, G., Caraguel, F., Arrufat, S., Remark, R., Romagné, F., Morel, Y., Narni-Mancinelli, E., & Vivier, E.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 177
- Issue
- 7
- Pages
- 1701-1713.e16
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2947619927
- Cited by
- 439
- References
- 77
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.